A Randomized Trial of the Rapamycin Target Eluting Stent for the Treatment of Symptomatic Cerebral Artery Atherosclerotic Disease（TARGET-DREAM）
Clinical trial NCT06925971 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06925971
- Sponsor
- MicroPort NeuroTech Co., Ltd.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-04-15
- Primary completion
- 2027-10-01
- Enrollment
- 279
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.